LDS/Medical Tests/Mu-opioid receptor 1 (OPRM1) Genotyping

Mu-opioid receptor 1 (OPRM1) Genotyping

The mu-opioid receptor (OPRM1) is the molecular target of many opioid drugs. These include many opioid agonists and antagonists. Opioid agonists are frequently used as pain management agents, such as morphine and fentanyl. One of the effects of binding of opioid agonists to OPRM1 is to increase release of beta-endorphins, which subsequently triggers release of dopamine and stimulates cravings. Naltrexone, an opioid antagonist, is widely used to treat opioid, and alcohol addiction. Naltrexone binds to OPRM1, which prevents beta-endorphin to bind and reduces the craving for abused substances.

Genetic variation (SNP) in OPRM1 is associated with the pharmacodynamics of opioid drugs by directly affecting the binding affinities of opioids with OPRM1. However, the effect of OPRM1 variation to different opioid agents may vary. The commonly known SNP in OPRM1 is 118 A>G polymorphism (rs1799971) in exon 1, which results in an amino acid change, Asn40Asp. This is also known as A355G (Asn102Asp). Frequency of the 118G SNP is largely variable in different ethnicities (African Americans 4%, Caucasians 14%, Hispanics 24%, Asians 25-47.4%). The consequence of the 118G variation is loss of a putative N-glycosylation site in the extracellular receptor region, which lowers the cell-surface OPRM1 receptor availability and likely causes the decrease of OPRM1 mRNA and protein expression. Studies have shown that 118G carriers have better outcomes with naltrexone therapy with lower rate of relapse, and a longer time to return to heavy drinking. Another study also indicated that 118G allele carriers had a higher rate of good clinical outcome than the 118A/A individuals. Hence, individuals with 118G variants are consistent with decreased sensitivity to opioid agonists and increased sensitivity to opioid antagonists.

  • Predict therapeutic response to opioid medications
  • Determine the optimal therapeutic strategy for individuals who may need higher or lower opioid dosage to achieve adequate pain management
  • Monitor responses to naltrexone management for the treatment of alcohol and/or opioid dependency
OPRM1 expression and activity are decreased in 118 GA and 118 GG alleles.

118 AA (355 AA)

 

 

Polymerase chain reaction (PCR) and high-resolution melting analysis, Real-time PCR and allele-specific probe (ARMS), Sequencing.

Blood & Saliva

Whole blood (EDTA), saliva, buccal swabs. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Therapeutic drug monitoring is the standard of care for monitoring patients on opioids. Drug toxicity tests and clinical assessments are recommended for other drugs; other CYP enzymes such as CYP2D6, CYP2C19, and CYP2C9.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login